Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Gefitinib-induced Myositis: A Novel Case Report
Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007.ABSTRACTChemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (E...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 2, 2023 Category: Drugs & Pharmacology Authors: Tatsuhiko Sakamoto Yoshitaka Saito Yoh Takekuma Eiki Kikuchi Mitsuru Sugawara Source Type: research
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
CONCLUSIONS: Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC.PMID:37379430 | DOI:10.1158/1078-0432.CCR-22-3146 (Source: Cell Research)
Source: Cell Research - June 28, 2023 Category: Cytology Authors: Jhanelle E Gray Myung-Ju Ahn Geoffrey R Oxnard Frances A Shepherd Fumio Imamura Ying Cheng Isamu Okamoto Byoung Chul Cho Meng-Chih Lin Yi-Long Wu Margarita Majem Oliver Gautschi Michael Boyer Krishna C Bulusu Aleksandra Markovets J Carl Barrett Rachel Hod Source Type: research
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
CONCLUSIONS: Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC.PMID:37379430 | DOI:10.1158/1078-0432.CCR-22-3146 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 28, 2023 Category: Cancer & Oncology Authors: Jhanelle E Gray Myung-Ju Ahn Geoffrey R Oxnard Frances A Shepherd Fumio Imamura Ying Cheng Isamu Okamoto Byoung Chul Cho Meng-Chih Lin Yi-Long Wu Margarita Majem Oliver Gautschi Michael Boyer Krishna C Bulusu Aleksandra Markovets J Carl Barrett Rachel Hod Source Type: research
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
CONCLUSIONS: Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC.PMID:37379430 | DOI:10.1158/1078-0432.CCR-22-3146 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - June 28, 2023 Category: Cancer & Oncology Authors: Jhanelle E Gray Myung-Ju Ahn Geoffrey R Oxnard Frances A Shepherd Fumio Imamura Ying Cheng Isamu Okamoto Byoung Chul Cho Meng-Chih Lin Yi-Long Wu Margarita Majem Oliver Gautschi Michael Boyer Krishna C Bulusu Aleksandra Markovets J Carl Barrett Rachel Hod Source Type: research
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
CONCLUSIONS: Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC.PMID:37379430 | DOI:10.1158/1078-0432.CCR-22-3146 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 28, 2023 Category: Cancer & Oncology Authors: Jhanelle E Gray Myung-Ju Ahn Geoffrey R Oxnard Frances A Shepherd Fumio Imamura Ying Cheng Isamu Okamoto Byoung Chul Cho Meng-Chih Lin Yi-Long Wu Margarita Majem Oliver Gautschi Michael Boyer Krishna C Bulusu Aleksandra Markovets J Carl Barrett Rachel Hod Source Type: research
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
CONCLUSIONS: Plasma EGFRm analysis as early as 3 weeks on-treatment has the potential to predict outcomes in EGFRm advanced NSCLC.PMID:37379430 | DOI:10.1158/1078-0432.CCR-22-3146 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - June 28, 2023 Category: Cancer & Oncology Authors: Jhanelle E Gray Myung-Ju Ahn Geoffrey R Oxnard Frances A Shepherd Fumio Imamura Ying Cheng Isamu Okamoto Byoung Chul Cho Meng-Chih Lin Yi-Long Wu Margarita Majem Oliver Gautschi Michael Boyer Krishna C Bulusu Aleksandra Markovets J Carl Barrett Rachel Hod Source Type: research
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
Pleural mesothelioma (PM) is a rare but aggressive cancer with poor prognosis, primarily caused by asbestos occupational exposure [1]. PM ’s earliest event and hallmark is the increased expression of proteins involved in neo-angiogenesis. Expression of multiple proangiogenic cytokines, including vascular endothelial growth factor (VEGF), has been shown to correlate with increased microvasculature vessel density (MVD) [2]. High serum VEGF concentrations correlated with worse prognosis in PM patients accrued to the phase 3 Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS), which assessed bevacizumab combined with chem...
Source: Lung Cancer - June 25, 2023 Category: Cancer & Oncology Authors: Gu énaëlle Levallet, Fatéméh Dubois, Nicolas Elie, Christian Creveuil, Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Sylvie Lantuejoul, Julien Mazières, Laurent Greillier, Clarisse Audigier-Valette, Emmanuel Bergot, Denis Moro-Sibilot, Olivier M Source Type: research
